Invention Grant
- Patent Title: Antibodies that bind EGFR and cMET
-
Application No.: US16637464Application Date: 2018-08-09
-
Publication No.: US11773170B2Publication Date: 2023-10-03
- Inventor: Cecilia Anna Wilhelmina Geuijen , Robertus Cornelis Roovers , Mark Throsby , Cornelis Adriaan De Kruif , Ton Logtenberg
- Applicant: MERUS N.V.
- Applicant Address: NL Utrecht
- Assignee: MERUS N.V.
- Current Assignee: MERUS N.V.
- Current Assignee Address: NL Utrecht
- Agency: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
- Agent Paul Calvo
- Priority: EP 185572 2017.08.09
- International Application: PCT/NL2018/050537 2018.08.09
- International Announcement: WO2019/031965A 2019.02.14
- Date entered country: 2020-02-07
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; C07K16/40 ; A61K39/00

Abstract:
The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.
Public/Granted literature
- US20200247892A1 ANTIBODIES THAT BIND EGFR AND CMET Public/Granted day:2020-08-06
Information query